**OBJECTIVE:** Pharmaceutical pricing is characterized by a consistent variability across markets. Identifying economic differences related to the benefit to cost ratio and designing strategies for such variability. Stricter regulatory hurdles, market landscape, challenging negotiation processes, varying business strategies, and sometimes unannounced outcomes of pharma launch decisions concur in the final price for a specific drug. A better understanding of pricing trends and additional evidence to reduce uncertainty. These objectives will be traded-off between different stakeholder needs, flexibility, responsiveness, and rigor as well as the flexibility to revise decisions on access when new evidence becomes available. The ENCePP WG on HTA has the potential to become a capacity building tool for regulatory and HTA agencies to develop research structures aimed at complementing the evidence generation for MA and market access. Post-authorisation studies developed under the auspices of ENCePP could provide new safety and clinical effectiveness information for Regulators.

**METHODS:** Using PRICENTRIC™ data, we collected ex-factory prices for various oncology products, and we defined whether a country fell into a HTA system or free pricing group. We also compared the product prices to GDP per capita (International Monetary Fund 2012) to investigate trends between the two parameters. The analysis investigates two key areas: 1. Difference in price depends on social, economic, and regional drivers determined by the nature and complexity of market access processes. 2. The relationship between prices and GDP per capita across countries. **RESULTS:** The US and Germany have the highest prices of all studied countries. They are also the only two countries where prices are freely set by manufacturers. Prices are slightly higher in Europe than the US and are often lower in developing countries. The UK having strong HTA authorities and pricing regulations do have a small correlation with the social policies in place. The analysis of the trends and differences of prices and economic policies are discussed.

**CONCLUSION:** the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks. This podium presentation will present original research aimed to qualify strategies to demonstrate how the benefits of ongoing collaborations far outweigh the risks.